Hepatogastroenterology Department, Hôpital Saint Joseph, Marseille, France.
Hepatogastroenterology Department, Hôpital Privé Jean Mermoz, Lyon, France.
Endoscopy. 2019 May;51(5):436-443. doi: 10.1055/a-0757-7714. Epub 2018 Nov 19.
The aim of this prospective multicenter study was to compare a flexible 19 G needle with nitinol shaft (19 G Flex) with a standard 22 G needle for transduodenal endoscopic ultrasound (EUS)-guided sampling of pancreatic head tumors.
Patients with pancreatic head tumors requiring tissue diagnosis were randomized into two arms: puncture with either a 19 G Flex needle or a 22 G needle. The primary end point was diagnostic accuracy for malignancy. The secondary end points were ergonomic scores, sample cytohistological quality, and complications. A 6-month follow-up was performed.
125 patients were randomized and 122 were analyzed: 59 patients in the 19 G Flex arm and 63 patients in the 22 G arm. The final diagnosis was malignancy in 111 patients and benign condition in 11. In intention-to-treat analysis, the diagnostic accuracy for malignancy of the 19 G Flex and 22 G needles was 69.5 % (95 % confidence interval [CI] 56.1 % - 80.8 %) vs. 87.3 % (95 %CI 76.5 % - 94.4 %), respectively ( = 0.02). In per-protocol analysis excluding eight technical failures in the 19 G Flex group, the diagnostic accuracy of the 19 G Flex and 22 G needles was not statistically different: 80.4 % (95 %CI 66.9 % - 90.2 %) vs. 87.3 % (95 %CI 76.5 % - 94.4 %; = 0.12). Technical success was higher in the 22 G arm than in the 19 G Flex arm: 100 % (95 %CI 94.3 % - 100 %) vs. 86.4 % (95 %CI 75.0 % - 94.0 %), respectively ( = 0.003). Transduodenal EUS-guided sampling was more difficult with the 19 G Flex (odds ratio 0.68, 95 %CI 0.47 - 0.97). CONCLUSION : The 19 G Flex needle was inferior to a standard 22 G needle in diagnosing pancreatic head cancer and more difficult to use in the transduodenal approach.
本前瞻性多中心研究旨在比较新型 19 G Flex (带镍钛诺针杆)与标准 22 G 针在经十二指肠超声内镜(EUS)引导下胰腺头部肿瘤穿刺活检中的应用。
需要组织学诊断的胰腺头部肿瘤患者被随机分为两组:19 G Flex 组和 22 G 组分别进行穿刺。主要终点是恶性肿瘤的诊断准确性。次要终点是手术操作的舒适度评分、样本细胞病理学质量和并发症。进行 6 个月的随访。
125 例患者随机分组,122 例患者被纳入分析:19 G Flex 组 59 例,22 G 组 63 例。最终诊断结果为恶性肿瘤 111 例,良性病变 11 例。意向性治疗分析中,19 G Flex 组和 22 G 组的恶性肿瘤诊断准确性分别为 69.5%(95%置信区间 56.1%-80.8%)和 87.3%(95%置信区间 76.5%-94.4%)( = 0.02)。排除 19 G Flex 组 8 例技术失败病例后,19 G Flex 组和 22 G 组的诊断准确性无统计学差异:80.4%(95%置信区间 66.9%-90.2%)和 87.3%(95%置信区间 76.5%-94.4%)( = 0.12)。22 G 组的技术成功率高于 19 G Flex 组:100%(95%置信区间 94.3%-100%)和 86.4%(95%置信区间 75.0%-94.0%)( = 0.003)。19 G Flex 组经十二指肠超声内镜引导下取样更困难(优势比 0.68,95%置信区间 0.47-0.97)。
与标准 22 G 针相比,新型 19 G Flex 针在诊断胰腺头部癌症方面表现较差,且在经十二指肠途径使用时更困难。